In Pharma 3.0, the need to invest in new outcomes-focused business models will add a new demand on the shrinking pool of available funds. We examine these shifts through our Capital Agenda framework.

https://vshow.on24.com/vshow/globalcenters/content/449013

IPO activity Sector specific insights Pharmaceutical industry insights Global insights Merger & Acquisitions (M&A) Capital agenda Life Science industry insights

Thought leadership/Insights